Retatrutide
Triple GIP/GLP-1/glucagon receptor research peptide supplied for in-vitro receptor-binding research.
Every lot of Retatrutide is analysed against the specification below before any vial is released.
| Parameter | Result | Method | |
|---|---|---|---|
| Appearance | White lyophilised powder | Visual | White lyophilised powder |
| Purity | ≥ 99.00% | HPLC | ≥ 95% |
| Identity | Confirmed | HPLC / MS | Meets specification |
| Heavy metals | Not detected | ICP-MS | Pass |
| Sterility | No growth | PCR | Pass |
| Endotoxin | Within limit | USP <85> | Report |
Analysis is carried out on every lot before release. If you are supplying material onward, run your own confirmatory testing on arrival — our work supports yours, it does not replace it.
- Presentation
- 30 mg / vial
- Molecular formula
- C221H342N46O68
- Molecular weight
- 4731.3 g/mol
- CAS
- 2381089-83-2
- Grade
- Research use only (RUO)
You'll sign in at checkout — free, and takes a moment.
Buy 2, get the 3rd 60% off. Buy 4, get 2 free — applied automatically at checkout. Or take 20% off with code PEAKSALE.
For laboratory and research purposes only. Not for human or animal consumption.
Peer-reviewed research on Retatrutide, indexed in PubMed. Listed so you can read the primary sources directly.
- Diabetes Obes MetabRetatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials
Giblin K, Kaplan LM, Somers VK et al.
- Expert Rev Clin PharmacolRetatrutide in type 2 diabetes mellitus and obesity: an overview
Panou T, Gouveri E, Popovic DS et al.
- LancetEfficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
Bajaj HS, Welch M, Shah P et al.
- Proc (Bayl Univ Med Cent)Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials
Abdrabou Abouelmagd A, Abdelrehim AM, Bashir MN et al.
- BiomoleculesRetatrutide-A Game Changer in Obesity Pharmacotherapy
Katsi V, Koutsopoulos G, Fragoulis C et al.
- Lancet Diabetes EndocrinolEffects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial
Coskun T, Wu Q, Schloot NC et al.
These papers are the published research on this molecule. They are not a claim about this product, and nothing here describes an intended use. All material is supplied for laboratory research only.